Wellbeing Digital to Participate in Microdose Wonderland Miami Conference
Vancouver, British Columbia, October 25, 2022 / GlobeNewswire / – Wellbeing Digital Sciences Inc. (“Wellbeing”or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental health care company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at this years’ Wonderland Miami Conference taking place on November 3 to November 5,2022 at the Mana Wynwood ConventionCentre.
Wonderland is one of the world’s largest conferences in the psychedelic medicine sector. It provides an opportunity to discover the world of psychedelic medicine, and is attended by some of the leading founders, investors, therapists, practitioners, researchers, thought leaders, innovators, and media from around the globe.
Najla Guthrie will participate on 3 panels:
November 4 at 9:30 a.m. ET- The Politics of PsychedelicMedicine - Will the evidence from psychedelic medicine research move politicians to develop a more rational and progressive drug policy?
November 4 at 5:00 p.m. ET- Building the Last Mile – Building centers of excellence for next generation therapies.
November 5 at 12:20 p.m. ET- Ketamine for Pain & Depression from RandomizedClinical Trials to Real Life Evidence- What does the current data showfor using ketamine for pain and depression? The panel will explore how to connect trial results with personalized ketamine treatments.
Register to attend here.
For more information about the conference, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at email@example.com.
ABOUTWELLBEING DIGITAL SCIENCES
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.
On behalf of:
For further information, please contact:
VP ofMarketing & Investment Relations
Notice RegardingForward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.